AVROBIO Inc. [AVRO] stock is down -14.05 while the S&P 500 has fallen -0.17% on Thursday, 11/19/20. While at the time of this article, AVRO ATR is sitting at 1.24. This stock’s volatility for the past week remained at 6.65%, while it was 8.45% for the past 30-day period. AVRO has fallen -$2.38 from the previous closing price of $16.98 on volume of 0.71 million shares.
On 19, November 2020, AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock. According to news published on Yahoo Finance, AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will total approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by the company. The offering is expected to close on or about Nov. 24, 2020, subject to customary closing conditions.
Analyst Birdseye View:
The most recent analyst activity for AVROBIO Inc. [NASDAQ:AVRO] stock was on March 31, 2020, when it was Downgrade with a Neutral rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $13. On June 27, 2019, Mizuho Initiated a Buy rating and boosted its price target on this stock to $28. On April 05, 2019, Janney Initiated a Buy rating. On October 10, 2018, Guggenheim Initiated a Buy rating. On October 02, 2018, H.C. Wainwright Reiterated a Buy rating and boosted its amount target on this stock to $40. On September 17, 2018, H.C. Wainwright Initiated a Buy rating and boosted its target amount on this stock to $47. Wells Fargo elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $9.76 and a peak of $29.32. Right now, the middling Wall Street analyst 12-month amount mark is $36.00. At the most recent market close, shares of AVROBIO Inc. [NASDAQ:AVRO] were valued at $14.60.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 16.57 points at 1st support level, the second support level is making up to 16.17. But as of 1st resistance point, this stock is sitting at 17.43 and at 17.89 for 2nd resistance point.
AVROBIO Inc. [AVRO] reported its earnings at -$1.01 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.81/share signifying the difference of -0.2 and -24.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.8 calling estimates for -$0.76/share with the difference of -0.04 depicting the surprise of -5.30%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for AVROBIO Inc. [NASDAQ:AVRO] is 9.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 13.34. Now if looking for a valuation of this stock’s amount to book ratio is 3.42.
The most recent insider trade was by MACKAY GEOFFREY, See Remarks, and it was the sale of 1400.0 shares on Feb 12. PAIGE CHRISTOPHER, the Director, completed a sale of 15000.0 shares on Feb 11. On Feb 11, MACKAY GEOFFREY, See Remarks, completed a sale of 63000.0 shares.